Summary
Thermo Fisher Scientific Inc. (TMO) reported its first quarter 2005 financial results, showing a 7% year-over-year increase in revenues to $559.2 million. This growth was primarily driven by favorable currency translations and strategic acquisitions, partially offset by a slight decline in organic sales, particularly from pharmaceutical customers. The company's profitability improved, with operating income rising to $59.7 million from $52.9 million in the prior year's quarter, leading to diluted earnings per share of $0.30. Looking ahead, TMO is actively pursuing growth through acquisitions, notably the pending $833.5 million acquisition of Kendro Laboratory Products, which will be financed through a combination of existing cash and a new bridge loan. The company also recently acquired Niton LLC for $40.5 million. Despite these investments and ongoing restructuring efforts, Thermo Fisher maintains a positive outlook on its liquidity, expecting its cash flow from operations, existing credit facilities, and anticipated refinancing to be sufficient to meet its capital requirements.
Key Highlights
- 1Total revenues increased by 7% to $559.2 million in Q1 2005 compared to $525.0 million in Q1 2004.
- 2Diluted earnings per share (EPS) rose to $0.30 in Q1 2005, up from $0.26 in Q1 2004.
- 3Operating income grew to $59.7 million, with the operating income margin improving to 10.7% from 10.1% year-over-year.
- 4The company completed the acquisition of Niton LLC for $40.5 million in March 2005.
- 5A significant acquisition of Kendro Laboratory Products for $833.5 million is expected to close in May 2005, to be financed with a bridge loan.
- 6Cash flow from operating activities decreased to $30.3 million in Q1 2005 from $46.6 million in Q1 2004, mainly due to working capital investments.
- 7The company ended the quarter with $351.6 million in cash and cash equivalents, an increase from $326.9 million at the end of 2004.